Amebiasis

Back

Background

Amebiasis is caused by Entamoeba histolytica (see the image below), a protozoan that is found worldwide (see Etiology).[1, 2, 3, 4] The highest prevalence of amebiasis is in developing countries where barriers between human feces and food and water supplies are inadequate (see Epidemiology).



View Image

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythr....

Although most cases of amebiasis are asymptomatic, dysentery and invasive extraintestinal disease can occur. Amebic liver abscess is the most common manifestation of invasive amebiasis, but other organs can also be involved, including pleuropulmonary, cardiac, cerebral, renal, genitourinary, peritoneal, and cutaneous sites. In developed countries, amebiasis primarily affects migrants from and travelers to endemic regions, men who have sex with men, and immunosuppressed or institutionalized individuals.

The National Institute of Allergy and Infectious Diseases (NIAID) has classified E histolytica as a category B biodefense pathogen because of its low infectious dose, environmental stability, resistance to chlorine, and ease of dissemination through contamination of food and water supplies.[5]

E histolytica is transmitted via ingestion of the cystic form (infective stage) of the protozoa. Viable in the environment for weeks to months, cysts can be found in fecally contaminated soil, fertilizer, or water or on the contaminated hands of food handlers. Fecal-oral transmission can also occur in the setting of anal sexual practices or direct rectal inoculation through colonic irrigation devices.

Excystation then occurs in the terminal ileum or colon, resulting in trophozoites (invasive form). The trophozoites can penetrate and invade the colonic mucosal barrier, leading to tissue destruction, secretory bloody diarrhea, and colitis resembling inflammatory bowel disease. In addition, the trophozoites can spread hematogenously via the portal circulation to the liver or even to more distant organs (see Pathophysiology).

E histolytica is capable of causing a spectrum of illnesses (see Presentation). Intestinal conditions resulting from E histolytica infection include the following:

Extraintestinal conditions resulting from E histolytica infection include the following:

Laboratory diagnosis of amebiasis is made by demonstrating the organism or by employing immunologic techniques. In addition to standard blood tests, other laboratory studies employed for diagnosis include microscopy, culture, serologic testing, and polymerase chain reaction (PCR) assay (see Workup).

Treatment of amebiasis includes pharmacologic therapy, surgical intervention, and preventive measures, as appropriate (see Treatment). Most individuals with amebiasis may be treated on an outpatient basis, though several clinical scenarios may favor inpatient care.

See Common Intestinal Parasites, a Critical Images slideshow, to help make an accurate diagnosis.

Pathophysiology

E histolytica is a pseudopod-forming, nonflagellated protozoal parasite that causes proteolysis and tissue lysis (hence the species name) and can induce host-cell apoptosis (see the image below). Humans and perhaps nonhuman primates are the only natural hosts.



View Image

Life cycle of Entamoeba histolytica.

Ingestion of E histolytica cysts (see the first image below) from the environment is followed by excystation in the terminal ileum or colon to form highly motile trophozoites (see the second image below). Upon colonization of the colonic mucosa, the trophozoite may encyst and is then excreted in the feces, or it may invade the intestinal mucosal barrier and gain access to the bloodstream, whereby it is disseminated to the liver, lung, and other sites. Excreted cysts reach the environment to complete the cycle.



View Image

Entamoeba histolytica cyst. Image courtesy of Centers for Disease Control and Prevention.



View Image

Entamoeba histolytica trophozoite. Image courtesy of Centers for Disease Control and Prevention.

Disease may be caused by only a small number of cysts, but the processes of encystation and excystation are poorly understood. The adherence of trophozoites to colonic epithelial cells seems to be mediated by a galactose/N -acetylgalactosamine (GAL/GalNAc)–specific lectin,[4, 6, 7] a 260-kd surface protein containing a 170-kd subunit and a 35-kd subunit. A mucosal immunoglobulin A (IgA) response against this lectin can result in fewer recurrent infections.[8]

Both lytic and apoptotic pathways have been described. Cytolysis can be undertaken by amebapores, a family of peptides capable of forming pores in lipid bilayers.[4] Furthermore, in animal models of liver abscess, trophozoites induced apoptosis via a non-Fas and non–tumor necrosis factor (TNF)-α1 receptor pathway.[9] The amebapores, at sublytic concentrations, can also induce apoptosis.

Cysteine proteinases have been directly implicated in invasion and inflammation of the gut and may amplify interleukin (IL)-1–mediated inflammation by mimicking the action of human IL-1–converting enzyme, cleaving IL-1 precursor to its active form.[4, 10] The cysteine proteinases can also cleave and inactivate the anaphylatoxins C3a and C5a, as well as IgA and immunoglobulin G (IgG).[11, 12]

E histolytica possesses about 100 putative transmembrane kinases (TMKs), which are commonly divided into 9 subgroups. Of these, EhTMKB1-9 is expressed in proliferating trophozoites and induced by serum. In an animal model, it was found to be involved in phagocytosis and to play a role as a virulence factor in amebic colitis.[13] These findings suggest that TMKs such as EhTMKB1-9 may be attractive targets for future drug development.

Epithelial cells also produce various inflammatory mediators, including IL-1β, IL-8, and cyclooxygenase (COX)-2, leading to the attraction of neutrophils and macrophages.[14, 15] Corticosteroid therapy is known to worsen the clinical outcome, possibly because of its blunting effect on this innate immune response.

Additional host defenses, including the complement system, could be inhibited directly by the trophozoites, as is suggested by the finding that a region of the GAL/GalNAc–specific lectin showed antigenic crossreactivity with CD59, a membrane inhibitor of the C5b-9 attack complex in human red blood cells.[16]

Spread of amebiasis to the liver occurs via the portal blood. The pathogenic strains evade the complement-mediated lysis in the bloodstream. Trophozoites that reach the liver create unique abscesses with well-circumscribed regions of dead hepatocytes surrounded by few inflammatory cells and trophozoites and unaffected hepatocytes. These findings suggest that E histolytica organisms are able to kill hepatocytes without direct contact.[4]

Serum antibodies in patients with amebic liver abscess develop in 7 days and persist for as long as 10 years. A mucosal IgA response to E histolytica occurs during invasive amebiasis; however, no evidence suggests that invasive amebiasis is increased in incidence or severity in patients with IgA deficiency.

Cell-mediated immunity is important in limiting the disease and preventing recurrences. Antigen-specific blastogenic responses occur, leading to production of lymphokines, including interferon-delta, which activates the killing of E histolytica trophozoites by the macrophages. This killing depends on contact, oxidative pathways, nonoxidative pathways, and nitric oxide (NO).

Lymphokines, such as TNF-α, are capable of activating the amebicidal activity of neutrophils. Incubation of CD8+ lymphocytes with E histolytica antigens in vitro elicits cytotoxic T-cell activity against the trophozoites. During acute invasive amebiasis, T-cell response to E histolytica antigens is depressed by a parasite-induced serum factor.

Etiology

Amebiasis is a parasitic infection caused by the protozoal organism E histolytica, which can give rise both to intestinal disease (eg, colitis) and to various extraintestinal manifestations, including liver abscess (most common) and pleuropulmonary, cardiac, and cerebral dissemination.

The genus Entamoeba contains many species, some of which (ie, E histolytica, Entamoeba dispar, Entamoeba moshkovskii, Entamoeba bangladeshi, Entamoeba polecki, Entamoeba coli, and Entamoeba hartmanni) can reside in the human interstitial lumen. Of these, E histolytica is the only one definitely associated with disease, although a 2012 report suggested E moshkovskii to be the causative agent of diarrhea in infants.[17, 18] Although E dispar and E histolytica cannot be differentiated by means of direct examination, molecular techniques have demonstrated that they are indeed 2 different species, with E dispar being commensal (as in patients with HIV infection) and E histolytica pathogenic.[17]

It is currently believed that many individuals with Entamoeba infections are actually colonized with E dispar, which appears to be 10 times more common than E histolytica[17] ; however, in certain regions (eg, Brazil and Egypt), asymptomatic E dispar and E histolytica infections are equally prevalent.[4] In Western countries, approximately 20%-30% of men who have sex with men are colonized with E dispar.[17]

E histolytica is transmitted primarily through the fecal-oral route. Infective cysts can be found in fecally contaminated food and water supplies and contaminated hands of food handlers. Sexual transmission is possible, especially in the setting of oral-anal practices (anilingus). Poor nutrition, through its effect on immunity, has been found to be a risk factor for amebiasis.[19]

Epidemiology

United States statistics

The overall prevalence of amebiasis in the United States is approximately 4%. E dispar infection, which is always asymptomatic, is 10 times more common than E histolytica infection. Moreover, only 10% of E histolytica infections cause invasive disease. Therefore, only 1% of persons with stool microscopy findings that reveal Entamoeba develop symptomatic amebiasis.

Certain groups are predisposed to amebic colitis, including very young patients, pregnant women, recipients of corticosteroids, and malnourished individuals.[4] In 1993, a total of 2970 cases of amebiasis were reported to the Centers for Disease Control and Prevention (CDC); 33% of cases were reported in Hispanic immigrants and 17% in immigrants from Asia or the Pacific Islands.

An increased prevalence of amebiasis is noted in institutionalized persons (especially those with mental retardation), male homosexuals, and persons living in communal settings.

Travelers to endemic areas are at risk for infection and represent most US cases. It is estimated that 14 of every 1,000 returning travelers with diarrhea have amebiasis, which accounts for 12.5% of all microbiologically confirmed cases.[20] Travel to South Asia, the Middle East, and South America poses the highest risk. Amebic liver abscess has been reported after a median duration of 3 months but may occur years later.

The US national death certificate data from 1990 to 2007 identified 134 deaths from amebiasis. A declining trend of deaths has been noted, with a current rate of 5 deaths per year.[21] More than 40% of reported deaths occurred in residents of California and Texas, with US-born persons accounting for most amebiasis deaths.[22]

International statistics

Worldwide, approximately 50 million cases of invasive E histolytica disease occur each year, resulting in as many as 100,000 deaths. This represents the tip of the iceberg because only 10%-20% of infected individuals become symptomatic.[23, 24, 25] The incidence of amebiasis is higher in developing countries.[26] Amebiasis is the second leading cause of death due to parasitic diseases, killing about 40,000-100,000 people per year globally.[27]

Earlier estimates of E histolytica infection, based on examination of stool for ova and parasites, are inaccurate, because this test cannot differentiate E histolytica from E dispar and E moshkovskii. In developing countries, the prevalence of E histolytica, as determined by enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR) assay of stool from asymptomatic persons, ranges from 1% to 21%. On the basis of current techniques, it is estimated that 500 million people with Entamoeba infection are colonized by E dispar.[17]

The prevalence of Entamoeba infection is as high as 50% in areas of Central and South America, Africa, and Asia.[28] E histolytica seroprevalence studies in Mexico revealed that more than 8% of the population were positive.[29] In endemic areas, as many as 25% of patients may be carrying antibodies to E histolytica as a result of prior infections, which may be largely asymptomatic. The prevalence of asymptomatic E histolytica infections seem to be region-dependent; in Brazil, for example, it may be as high as 11%.

In Egypt, 38% of individuals presenting with acute diarrhea to an outpatient clinic were found to have amebic colitis.[4] A study in Bangladesh indicated that preschool children experienced 0.09 episodes of E histolytica -associated diarrhea and 0.03 episodes of amebic dysentery each year. In Hue City, Vietnam, the annual incidence of amebic liver abscess was reported to be 21 cases per 100,000 inhabitants.[30]

An epidemiologic study in Mexico City reported that 9% of the population was infected with E histolytica in the 5-year to 10-year period preceding the study. Various factors, such as poor education, poverty, overcrowding, contaminated water supply, and unsanitary conditions, contributed to fecal-oral transmission.

Several studies have evaluated the association of amebiasis with AIDS.[31, 32, 33, 34, 35, 36] The impact of the AIDS pandemic on the prevalence of invasive amebiasis remains controversial. Some reports suggest that invasive amebiasis is not increased among patients with HIV infection[37] ; however, others suggest that amebic liver abscess is an emerging parasite infection in individuals with HIV infection in disease-endemic areas, as well as in non–disease-endemic areas.[38, 38]

Of 31 patients with amebic liver abscess at Seoul National University Hospital from 1990 to 2005, 10 (32%) were HIV-positive.[39] In a case-control study of persons seeking voluntary counseling and testing for HIV infection, homosexual activity, fecal-oral contamination, lower educational achievement, and older age were associated with increased risk of amebiasis.[40]

Age-related demographics

Symptomatic intestinal amebiasis occurs in all age groups. Liver abscesses due to amebiasis are 10 times more frequent in adults than in children. Very young children seem to be predisposed to fulminant colitis.

Sex-related demographics

Amebic colitis affects both sexes equally.[4] However, invasive amebiasis is much more common in adult males than in females. In particular, amebic liver abscess is 7-12 times more common in men than in women, with a predominance among men aged 18-50 years. The reason for this disparity is unknown, though hormonal effects may be implicated, as the prevalence of amebic liver abscess is also increased among postmenopausal women. Alcohol may also be an important risk factor.

Among prepubertal children, amebic liver abscess is equally common in both sexes.[4] Acuna-Soto et al noted that asymptomatic E histolytica infection is distributed equally between sexes.[41] Therefore, the higher proportion of adult males with invasive amebiasis may be due to a male susceptibility to invasive disease.

Race-related demographics

In Japan and Taiwan, HIV seropositivity is a risk factor for invasive extraintestinal amebiasis.[38] This association has not been observed elsewhere. Among HIV-positive patients, homosexual intercourse, and not immunosuppressed status, seems to be a risk factor for amebic colitis.[42]

Prognosis

Amebic infections can lead to significant morbidity while causing variable mortality. In terms of protozoan-associated mortality, amebiasis is second only to malaria. The severity of amebiasis is increased in the following groups:

Intestinal infections due to amebiasis generally respond well to appropriate therapy, though it should be kept in mind that previous infection and treatment will not protect against future colonization or recurrent invasive amebiasis.

Asymptomatic intestinal amebiasis occurs in 90% of infected individuals. However, only 4%-10% of individuals with asymptomatic amebiasis who were monitored for 1 year eventually developed colitis or extraintestinal disease.[17]

With the introduction of effective medical treatment, mortality has fallen below 1% for patients with uncomplicated amebic liver abscess. However, amebic liver abscess can be complicated by sudden intraperitoneal rupture in 2-7% of patients, and this complication leads to a higher mortality.[4]

Case-fatality rates associated with amebic colitis range from 1.9% to 9.1%. Amebic colitis evolves to fulminant necrotizing colitis or rupture in approximately 0.5% of cases; in such cases, mortality may exceeds 40%[43] or even, according to some reports, 50%.

Pleuropulmonary amebiasis has a 15-20% mortality rate. Amebic pericarditis has a case-fatality rate of 40%. Cerebral amebiasis carries a very high mortality (90%).

A study of 134 deaths in the United States from 1990 to 2007 found that mortality was highest in men, Hispanics, Asian/Pacific Islanders, and people aged 75 years or older.[22] An association with HIV infection was also observed. Although deaths declined during the course of the study, more than 40% occurred in California and Texas. US-born persons accounted for the majority of amebiasis deaths; however, all of the fatalities in Asian/Pacific Islanders and 60% of the deaths in Hispanics were in foreign-born individuals.

Patient Education

Individuals traveling to endemic areas should be advised on practices that minimize the risk of amebiasis, such as the following:

History

The incubation period for E histolytica infection is commonly 2-4 weeks but may range from a few days to years. The clinical spectrum of amebiasis ranges from asymptomatic infection to fulminant colitis and peritonitis to extraintestinal amebiasis, the most common form of which is amebic liver abscess.

Amebiasis is more severe in very young patients, in elderly patients, and in patients receiving corticosteroids. The clinical expression of amebiasis may be related to geography. For instance, amebic colitis is the predominant presentation in Egypt, whereas amebic liver abscesses predominate in South Africa.

Asymptomatic infections are common after ingestion of the parasite. E dispar does not cause invasive disease or antibody production. As many as 90% of E histolytica infections are also asymptomatic. The infection is self-limited but may be recurrent. It is not possible to distinguish between E histolytica and E dispar on clinical grounds; only antigen detection tests can make this distinction.

Amebic colitis

Amebic colitis is gradual in onset, with symptoms presenting over 1-2 weeks; this pattern distinguishes this condition from bacterial dysentery. Diarrhea is the most common symptom. Patients with amebic colitis typically present with cramping abdominal pain, watery or bloody diarrhea, and weight loss or anorexia. Fever is noted in 10-30% of patients. Intestinal amebiasis may mimic acute appendicitis.[44] Rectal bleeding without diarrhea can occur, especially in children.

Fulminant amebic colitis is a rare complication of amebic dysentery (< 0.5% of cases). It presents with the rapid onset of severe bloody diarrhea, severe abdominal pain, and evidence of peritonitis and fever. Predisposing factors for fulminant colitis include poor nutrition, pregnancy, corticosteroid use, and very young age (< 2 years). Intestinal perforation is common. Patients may develop toxic megacolon, which is typically associated with the use of corticosteroids. Mortality from fulminant amebic colitis may exceed 40%.

Chronic amebic colitis is clinically similar to inflammatory bowel disease (IBD). Recurrent episodes of bloody diarrhea and vague abdominal discomfort develop in 90% of patients with chronic amebic colitis who have antibodies to E histolytica. Amebic colitis should be ruled out before treatment of suspected IBD because corticosteroid therapy worsens amebiasis.

Amebic liver abscess

Amebic liver abscess is the most common form of extraintestinal amebiasis.[45] It occurs in as many as 5% of patients with symptomatic intestinal amebiasis and is 10 times as frequent in men as in women. Approximately 80% of patients with amebic liver abscess present within 2-4 weeks of infection. An estimated 95% of amebic liver abscesses related to travel develop within 5 months, though some may not manifest until years after travel to or residency in an endemic area.

The most typical presentation of amebic liver abscess is fever (in 85-90% of cases, in contrast to amebic colitis), right upper quadrant pain, and tenderness of less than 10 days’ duration. Involvement of the diaphragmatic surface of the liver may lead to right-side pleuritic pain or referred shoulder pain. Acute abdominal symptoms and signs should prompt rapid investigation for intraperitoneal rupture.

Associated gastrointestinal (GI) symptoms occur in 10-35% of patients and include nausea, vomiting, abdominal distention, diarrhea, and constipation. Approximately 40% of patients who have amebic liver abscess do not have a history of prior bowel symptoms. Although 60-70% of patients with amebic liver abscess do not have concomitant colitis, a history of dysentery within the previous year may be obtained. In a 2014 study of routine colonoscopy in patients with amebic liver abscess, colonic involvement was noted in two thirds of cases.[46] When colon was involved, right colonic lesion was universally present.

A small subset of patients with amebic liver abscess have a subacute presentation with vague abdominal discomfort, weight loss or anorexia, and anemia. Jaundice is unusual. Cough can occur. A history of alcohol abuse is common, but whether a causal relation exists is unclear.

Other manifestations of amebiasis

Ameboma

Ameboma, a less common form of intestinal disease, arises from the formation of annular colonic granulation in response to the infecting organisms, which results in a large local lesion of the bowel. It presents as a right lower quadrant abdominal mass, which may be mistaken for carcinoma, tuberculosis, Crohn disease, actinomycosis, or lymphoma. Biopsy findings assist in establishing the correct diagnosis. Rectal masses that resemble carcinoma on colonoscopy have also been noted.[47]

Pleuropulmonary amebiasis

Pleuropulmonary amebiasis is most commonly the result of contiguous spread from a liver abscess rupturing through the right hemidiaphragm.[48] However, a case of amebic lung abscess acquired through hematogenous spread has been reported. The typical age group is 20-40 years. The male-to-female ratio is 10:1.

Approximately 10% of patients with amebic liver abscess develop pleuropulmonary amebiasis, which presents with cough, pleuritic pain, and dyspnea. A hepatobronchial fistula is an unusual problem characterized by the expectoration of sputum resembling anchovy paste. The trophozoites of E histolytica may be found in the sputum sample. Primary amebic pneumonia as a result of hematogenous spread has been reported, though rarely.[49]

Cerebral amebiasis

Amebic abscesses resulting from hematogenous spread have occasionally been described in the brain. Cerebral amebiasis occurs in 0.6% of amebic liver abscess cases. Patients commonly present with the abrupt onset of nausea, vomiting, headache, and mental status changes. Computed tomography (CT) reveals irregular lesions without a surrounding capsule or enhancement. A tissue biopsy sample reveals the trophozoites. Progression can be very rapid, sometimes leading to death within 12-72 hours.

Amebic peritonitis

Amebic peritonitis is generally secondary to a ruptured liver abscess. Left-lobe liver abscesses are more likely to rupture. Patients present with fever and a rigid distended abdomen. Roughly 2-7% of liver abscesses rupture into the peritoneum.

Amebic pericarditis

Amebic pericarditis is rare but is the most serious complication of hepatic amebiasis. It is usually caused by a rupture of a left-liver lobe abscess and occurs in 3% of patients with hepatic amebiasis. It presents with chest pain and the features of congestive heart failure.

Genitourinary amebiasis

Genitourinary involvement may cause painful genital ulcers or fallopian tube amebiasis.

Amebic appendicitis

In countries of high prevalence, amebiasis occasionally presents as acute appendicitis.[50]

Physical Examination

Patients with acute amebic colitis may have lower quadrant abdominal tenderness (12-85% of cases). Fever is noted in only a minority of patients (10-30%). Weight loss occurs in 40%. Dehydration is uncommon. Occult blood is nearly always present in stools (70-100%). Fulminant amebic colitis is commonly characterized by abdominal pain, distention, and rebound tenderness.

Amebic liver abscess may present with fever (85-90% of cases) and tender hepatomegaly (30-50%). Right lower intercostal tenderness may be elicited, particularly posteriorly (84-90%). Weight loss is noted in 33-50%. Breath sounds may be diminished at the right lung base, and rales may be heard. A small subset of patients has a subacute presentation with hepatomegaly, weight loss, and anemia. Jaundice is unusual (6-10%).

Other physical findings in amebiasis include the following:

Complications

Complications of amebic colitis include the following:

Complications of amebic liver abscess include the following:

Other complications due to amebiasis include the following[45, 51] :

Laboratory Studies

Laboratory diagnosis of amebiasis is made by demonstrating the organism or by employing immunologic techniques.[52, 53, 54, 55, 56]

Findings from basic blood tests may include the following:

Other laboratory studies employed for diagnosis include microscopy, culture, serologic testing, and polymerase chain reaction (PCR) assay.

Microscopy

Laboratory diagnosis of intestinal amoebiasis in developing countries still relies on labor-intensive and insensitive methods involving staining and microscopic examination of fresh stool smears for trophozoites that contain ingested red blood cells (see the image below).[57] The presence of intracytoplasmic RBCs in trophozoites is diagnostic of E histolytica infection, although some studies have demonstrated the same phenomenon with E dispar.[17]



View Image

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythr....

Examination of a single stool sample has a sensitivity of only 33-50%; however, examination of 3 stool samples over no more than 10 days can improve the detection rate to 85-95%. It should be kept in mind that routine microscopy cannot be relied on to distinguish the pathogenic E histolytica from the nonpathogenic E dispar, E bangladeshi, and E moshkovskii.

Stool leukocytes may be found, but in fewer numbers than in shigellosis.

Stool examination findings in patients with amebic liver abscess are usually negative. Repeated stool sampling in patients with proven amebic liver abscess is positive in 8-40% of cases. Identification of the parasite in a liver abscess aspirate is only 20% sensitive.

The World Health Organization (WHO) recommends that intestinal amebiasis be diagnosed with an E histolytica–specific test, thus rendering the classic ova-and-parasite stool examination obsolete.

Culture

Cultures can be performed either with fecal or rectal biopsy specimens or with liver abscess aspirates.[17] Culture has a success rate of 50-70%, but it is technically difficult. Overall, culture is less sensitive than microscopy.

Xenic cultivation, first introduced in 1925, is defined as the growth of the parasite in the presence of an undefined flora. This technique is still in use today, using modified Locke-egg media. Axenic cultivation, first achieved in 1961, involves growing the parasite in the absence of any other metabolizing cells. Only a few strains of E dispar have been reported to be viable in axenic cultures.

Antigen detection

Enzyme-linked immunosorbent assay (ELISA) is used to detect antigens from E histolytica in stool samples. Several kits are commercially available.[17]

Antigen-based ELISA kits using monoclonal antibodies against the galactose/N -acetylgalactosamine (GAL/GalNAc)–specific lectin of E histolytica (E histolytica II, TechLab, Blacksburg, VA) yield an overall sensitivity of 71-100% and a specificity of 93-100%. One study showed a much lower sensitivity (14.2%). In patients with amebic liver abscess, serum and liver aspirate antigen detection using the same kit was shown to yield a sensitivity of 96% in serum and 100% in liver aspirate.

Other stool detection kits use monoclonal antibodies against the serine-rich antigen of E histolytica (Optimum S; Merlin Diagnostika, Bornheim-Hersel, Germany) or against other specific antigens (Entamoeba CELISA-PATH, Cellabs, Brookvale, Australia; ProSpecT EIA, Remle Inc, Lenexa, KY).

No specific antigen tests are available for the detection of E dispar and E moshkovskii from clinical samples.

Antibody detection

Serum antibodies against amebae are present in 70-90% of individuals with symptomatic intestinal E histolytica infection.[17] Antiamebic antibodies are present in as many as 99% of individuals with liver abscess who have been symptomatic for longer than 1 week. Serologic examination should be repeated 1 week later in those with negative test on presentation. However, serologic tests do not distinguish new from past infection, because the seropositivity persists for years after an acute infection.

ELISA, the assay most commonly used worldwide, measures the presence of serum antilectin antibodies (immunoglobulin G [IgG]). The galactose lectin antigen is present in the serum of 75% of subjects with amebic liver abscess and may be particularly useful in patients presenting acutely, before an IgG antiamebic antibody response occurs. The sensitivity of ELISA for detection of antibodies to E histolytica in patients with amebic liver abscess is 97.9%, and its specificity is 94.8%. False-negative results can occur within the first 7-10 days after infection.

Immunofluorescent assay (IFA) is also rapid, reliable, and reproducible. In the setting of amebic liver abscess, the sensitivity and specificity of IFA were shown to be 93.6% and 96.7%, respectively.

Indirect hemagglutination assay (IHA) detects antibody specific for E histolytica. The antigen used in IHA consists of a crude extract of axenically cultured organisms. Antibody titers of more than 1:256 to the 170-kd subunit of the galactose-inhibitable adherence lectin are noted in approximately 95% of patients with extraintestinal amebiasis, 70% of patients with active intestinal infection, and 10% of asymptomatic individuals.

IHA is very specific (99.1%), but it is less sensitive than ELISA. It is not useful in differentiating acute infection from previous infection, because high titers may persist for years after successful treatment. False-positive reactions at titers higher than 1:256 are rare. ELISA has replaced IHA in most laboratories.[58]

Immunoelectrophoresis, counterimmunoelectrophoresis (CIE), and immunodiffusion (ID) use the precipitation property of antigen-antibody complexes in agar. CIE is time-consuming but has a sensitivity of 100% in invasive amebiasis. ID is simple to perform and thus ideal for laboratories that only rarely perform amebic serology; however, it requires a minimum of 24 hours, compared with 2 hours for IHA or ELISA. ID is slightly less sensitive than IHA and ELISA but is equally specific. Complement fixation (CF) is less sensitive than other techniques.

Although detection of immunoglobulin M (IgM) antibodies specific for E histolytica has been reported, sensitivity in patients with current invasive disease is only about 64%.

Polymerase chain reaction assay

A wide variety of PCR-based methods targeting different genes, including a small-subunit rRNA gene (18S rDNA), a 30-kd antigen gene, a serine-rich protein gene, a chitinase gene, a hemolysin gene, and extrachromosomal circular DNA, have been described for the detection and differentiation of E histolytica, E dispar, and E moshkovskii.[17]

Sensitivities can vary according to sampling and the specific target gene used. Field studies that directly compared PCR with stool culture or antigen-detection tests for the diagnosis of E histolytica infection found these methods to be comparably effective. PCR assay can also be used for detection of E histolytica in liver aspirates for the diagnosis of amoebic liver abscess.[59]

PCR-based tests have been strongly endorsed by the WHO. However, application of PCR-based methods in routine diagnosis is still very limited[60, 61, 62] ; the generation of nonspecific DNA fragments from environmental and clinical samples often leads to false-positive results.

Loop-mediated isothermal amplification assay

The loop-mediated isothermal amplification (LAMP) assay has been applied to the detection of E histolytica in cases of hepatic amebiasis. A study that compared this test with PCR testing in 50 patients with clinical suspicion of amebic liver abscess found that LAMP assay detected 5 additional abscesses that were missed by PCR assay.[63] The rapidity, operational simplicity, high specificity and sensitivity, and high yield of LAMP assay suggest that it may prove to be a better diagnostic tool than PCR assay for diagnosis of hepatic amebiasis.

Radiography, Ultrasonography, CT, and MRI

Chest radiography may reveal an elevated right hemidiaphragm and a right-side pleural effusion in patients with amebic liver abscess.

Both ultrasonography and CT scanning are sensitive but nonspecific for amebic liver abscess. Ultrasonography is preferred for the evaluation of amebic liver abscess because of its low cost, rapidity, and lack of adverse effects. CT may be slightly more sensitive than ultrasonography. In cerebral amebiasis, CT shows irregular lesions without a surrounding capsule or enhancement.

On ultrasonograms, amebic liver abscesses usually appear as a solitary homogenous hypoechoic round lesion in the posterosuperior aspect of the right lobe of the liver (70-80% of cases), though multiple abscesses may occur in some patients. In an ultrasonographic evaluation of 212 patients, 34 (16%) had multiple abscesses, 75 (35%) had an abscess in the left lobe, and the remaining 103 (49%) had a solitary abscess in the right lobe.

On CT scans with intravenous (IV) contrast, amebic liver abscess can appear as a rounded, low-attenuation lesion with an enhancing rim. Furthermore, the abscess may be homogenous or septated, with or without observable fluid levels.

Magnetic resonance imaging (MRI) reveals high signal intensity on T2-weighted images. Perilesional edema and enhancement of rim are noted after injection of gadolinium (86% of cases).

Complete resolution of liver abscess may take as long as 2 years. Repeat imaging is not indicated if the patient is otherwise doing well.

Liver Aspiration

Ultrasound- or CT-guided needle aspiration of the liver should be performed when a diagnosis must be established very rapidly; pyogenic liver abscess can present and appear in similarly to amebic liver abscess.

Liver abscess aspirate is usually an odorless thick yellow-brown liquid classically referred to as “anchovy paste.” This liquid lacks white blood cells (WBCs) as a result of lysis by the parasite. Amebae are visualized in the abscess fluid in a minority of patients with amebic liver abscess (see the image below). Liver aspiration is indicated only if abscesses are large (> 12 cm), abscess rupture is imminent, medical therapy has failed, or abscesses are present in the left lobe.



View Image

Entamoeba histolytica in liver aspirate, trichrome stain. Image courtesy of Centers for Disease Control and Prevention.

The aspirate can be sent for microscopy, culture, antigen detection, and PCR, where available. A Gram stain should also be performed if a pyogenic etiology is suspected clinically.

Lower GI Endoscopy

Rectosigmoidoscopy and colonoscopy with biopsy or scraping at the margin of a colonic mucosal ulcer provide valuable materials for diagnostic information in intestinal amebiasis. Tissue can be sent for microscopic evaluation, culture, and PCR assay, where available.

Indications for endoscopy in suspected intestinal amebiasis include the following:

Fulminant colitis is a relative contraindication to colonoscopy, because it increases the risk of intestinal perforation.

On endoscopic examination, small mucosal ulcers covered with yellowish exudates are observed. The mucosal lining between the ulcers appears normal. The mucosa resembles that seen in inflammatory bowel disease (IBD). Biopsy results and a scraping of ulcer edge may reveal trophozoites. Ameboma (a carcinomalike annular lesion) can also be seen, usually in the cecum and ascending colon.[4, 64]

Rectosigmoidoscopy and colonoscopy should be considered before steroids are used in patients with suspected IBD. In a multivariate analysis, the best combination of findings for predicting amebic colitis was the combination of cecal lesions, multiple lesions, and exudates.[65]

Histologic Findings

The intestinal biopsy specimen should be taken from the edge of ulcers and evaluated for motile trophozoites.

Histopathologic findings may include nonspecific mucosal thickening, multiple discrete ulcers separated by regions of normal-appearing colonic mucosa, diffusely inflamed and edematous mucosa, necrosis, or wall perforation (see the image below).



View Image

Gross pathology of intestinal ulcers due to amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Amebic invasion through the mucosa and into submucosal tissues is the hallmark of amebic colitis; lateral extension through the submucosal tissues gives rise to the classic flask-shaped ulcer of amebic colitis (see the images below).



View Image

Histopathology of amebiasis. Image courtesy of Centers for Disease Control and Prevention.



View Image

Histopathology of typical flask-shaped ulcer of intestinal amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Different chemical stains can be used (see the image below), including periodic acid−Schiff stain, which makes E histolytica appear magenta in color.



View Image

Trichrome stain of Entamoeba histolytica cyst in amebiasis. Each cyst has 4 nuclei with characteristically centrally located karyosomes. Cysts measure....

Approach Considerations

Treatment of amebiasis includes pharmacologic therapy, surgical intervention, and preventive measures, as appropriate. Most individuals with amebiasis may be treated on an outpatient basis. Several clinical scenarios may favor inpatient care, as follows:

Intestinal amebiasis may be mistakenly treated as if it were inflammatory bowel disease (IBD). Accordingly, in all patients with suspected IBD, lower gastrointestinal (GI) endoscopy should be performed before treatment with steroids is initiated.

The following consultations may be helpful:

Follow-up stool examination after therapy completion is recommended to ensure intestinal eradication. No special diet is recommended.

Pharmacologic Therapy

In endemic areas, asymptomatic infections are not treated. In nonendemic areas, however, asymptomatic infection should be treated[66] ; luminal agents that are minimally absorbed by the GI tract (eg, paromomycin, iodoquinol, and diloxanide furoate) are best suited for such therapy.[67, 68] This recommendation is based on 2 arguments: first, that invasive disease may develop, and second, that shedding of E histolytica cysts in the environment is a public health concern.[4]

Asymptomatic E dispar infections should not be treated, but because this organism is a marker of fecal-oral contamination, educational efforts should be initiated.[4]

Metronidazole is the mainstay of therapy for invasive amebiasis.[66, 69, 70] Tinidazole has been approved by the US Food and Drug Administration (FDA) for intestinal or extraintestinal amebiasis. Other nitroimidazoles with longer half-lives (ie, secnidazole and ornidazole) are currently unavailable in the United States.

Nitroimidazole therapy leads to clinical response in approximately 90% of patients with mild-to-moderate amebic colitis. Because intraluminal parasites are not affected by nitroimidazoles, nitroimidazole therapy for amebic colitis should be followed by treatment with a luminal agent (eg, paromomycin or diloxanide furoate) to prevent a relapse.[4] A 2019 Cochrane Database Review reported that tinidazole may be more effective than metronidazole and is associated with fewer adverse events.[71] Combination drug therapy may be more effective for reducing parasitological failure compared with metronidazole alone.[71]

Amebic liver abscess of up to 10 cm can be cured with metronidazole without drainage.[72] Drainage is reserved for larger abscesses, for patients who do not exhibit a clinical response to medical therapy by about 72 hours, or for left-lobe abscesses, which could rupture into the pericardium. Resolution of the abscess cavity on serial imaging takes months.[73] Treatment with a luminal agent should also follow.[4]

Chloroquine has also been used for patients with hepatic amebiasis. Dehydroemetine (available from the Centers for Disease Control and Prevention [CDC] Drug Service [404-639-3670]) has been successfully used but, because of its potential myocardial toxicity, is not preferred.

Broad-spectrum antibiotics may be added to treat bacterial superinfection in cases of fulminant amebic colitis and suspected perforation. Bacterial coinfection of amebic liver abscess has occasionally been observed (both before and as a complication of drainage), and adding antibiotics to the treatment regimen is reasonable in the absence of a prompt response to nitroimidazole therapy.

Loperamide should be avoided in the treatment of amebic colitis.[74]

Surgical and Percutaneous Intervention

Surgical intervention is required for acute abdomen that is due to any of the following[75] :

Surgical intervention is usually indicated in the following clinical scenarios[4] :

Unlike pyogenic liver abscess, uncomplicated amebic liver abscess generally responds to medical therapy alone; drainage is seldom necessary and is usually best avoided. When drainage is necessary, image-guided percutaneous intervention (ie, needle aspiration or catheter drainage[76] ) has replaced surgical intervention as the procedure of choice. The indications for drainage of amebic liver abscess include the following:

Percutaneous catheter drainage improves treatment outcomes in amebic empyema and is life-saving in amebic pericarditis. It should be used judiciously in the setting of localized intra-abdominal fluid collections.

Prevention

Amebiasis is prevented by eradicating fecal contamination of food and water through improved sanitation, hygiene, and water treatment. In nonendemic areas, disease transmission can be reduced by early treatment of carriers.

Amebic cysts are not killed by soap or low concentrations of chlorine or iodine; therefore, water in endemic areas should be boiled for more than 1 minute and vegetables should be washed with a detergent soap and soaked in acetic acid or vinegar for 10-15 minutes before consumption.

Avoiding sexual practices that involve fecal-oral contact may reduce the risk of sexual transmission of infective cysts. Because reinfection is possible, family members or close contacts of an index case should be screened.

Household contacts of patients with amebiasis should be screened to prevent spread.[77] Patients with a new diagnosis of inflammatory bowel disease and history of travel to an endemic area should be screened for amebiasis prior to corticosteroid or other immunosuppressive therapy, as fulminant amebic colitis may result from misdiagnosis.[77]

In humans, natural E histolytica infection does not seem to result in long-term immunity: individuals with a previous amebic liver abscess are as susceptible to a new infection as other members of the population are.[4]

Development of a vaccine for invasive amebiasis is still in its infancy.[78, 79, 80] Many components of the ameba are immunogenic and may serve as targets for a future vaccine, including the galactose/N -acetylgalactosamine lectin, the serine-rich E histolytica protein, cysteine proteinases, lipophosphoglycans, amebapores, and the 29-kd protein. Quach et al reviewed current strategies involved in the development of a vaccine against E histolytica.[81]

Medication Summary

Asymptomatic amebiasis in nonendemic areas should be treated with a luminal agent (iodoquinol, paromomycin, or diloxanide furoate) to eradicate infection. Asymptomatic Entamoeba dispar infections should not be treated, but education should be pursued.

Amebic colitis is treated first with a nitroimidazole derivative and then with a luminal agent to eradicate colonization. Paromomycin is safe, well tolerated, and effective in the treatment of intestinal amebiasis, including in patients with HIV infection.[82] Diloxanide is a dichloroacetamide derivative that is amebicidal against trophozoite and cyst forms of E histolytica. It is not available in the United States.

Amebic liver abscess can be cured without drainage by using metronidazole. Treatment with a luminal agent should also follow. Disseminated amebiasis should be treated with metronidazole, which can cross the brain-blood barrier. Empirical antibacterial therapy should be used concomitantly if perforated bowel is a concern.

Metronidazole (Flagyl)

Clinical Context:  Metronidazole kills trophozoites of Entamoeba histolytica in intestines and tissue but does not eradicate cysts from intestines. It appears to be absorbed into cells. Intermediate metabolized compounds are formed and bind DNA and inhibit protein synthesis, causing cell death. Antimicrobial effect may be due to production of free radicals. Metronidazole is indicated for invasive amebiasis.

Tinidazole (Tinidazole)

Clinical Context:  Tinidazole is a 5-nitroimidazole derivative used to treat susceptible protozoal infections. The mechanism by which it acts against Giardia and Entamoeba species is not known. Tinidazole is indicated for treatment of intestinal amebiasis and amebic liver abscess caused by E histolytica in adults and children aged 3 years and older.

Paromomycin

Clinical Context:  Paromomycin is an amebicidal and antibacterial aminoglycoside obtained from a strain of Streptomyces rimosus; it is poorly absorbed and is active only against the intraluminal form of amebiasis. Used to eradicate cysts of E histolytica after treatment with metronidazole or tinidazole for invasive disease.

Parasite biochemical pathways are sufficiently different from those of the human host to allow selective interference by chemotherapeutic agents in relatively small doses.

Iodoquinol (Yodoxin)

Clinical Context:  Iodoquinol is a halogenated hydroxyquinoline that is a luminal amebicide; it acts primarily in the bowel lumen because it is poorly absorbed. It is best tolerated when given with meals. Because iodoquinol is active only against intraluminal form of amebiasis, it is used to eradicate cysts of E histolytica after treatment of invasive disease.

Chloroquine phosphate (Aralen)

Clinical Context:  Chloroquine phosphate inhibits growth by concentrating within acid vesicles of the parasite, thereby increasing the organism's internal pH. It also inhibits the organism's hemoglobin utilization and metabolism.

In vitro studies involving trophozoites of E histolytica demonstrate that chloroquine possesses amebicidal activity comparable to that of emetine. It is highly effective in treating amebic liver abscess when administered with emetine or dehydroemetine; however, like emetine and dehydroemetine, it is not effective against luminal forms. Irreversible retinal damage does not occur with the dosage and treatment duration used for treatment of hepatic amebiasis.

Dehydroemetine (Mebadin)

Clinical Context:  Dehydroemetine is preferred to emetine because it is less toxic. It eradicates amebic tissue infections, including liver abscess, but does not act on luminal forms. To eradicate a bowel luminal infection, a luminal amebicide must be used as well. Dehydroemetine is effective only against trophozoites, not against cysts. In the United States, it is available only from the Parasitic Disease Drug Service of the Centers for Disease Control and Prevention (CDC).

Class Summary

Several agents are active against anaerobic bacteria and protozoa. Metronidazole is the drug of choice for symptomatic, invasive disease; paromomycin is the drug of choice for noninvasive disease. Because parasites persist in the intestines of 40-60% of patients treated with metronidazole, this drug should be followed with paromomycin to cure luminal infection. Do not give the 2 medications at the same time; the diarrhea that often results from paromomycin might be confused with continuing active intestinal disease from the parasite.

What is amebiasis?What are the signs and symptoms of amebiasis?Which groups are at highest risk for amebiasis?How is Entamoeba histolytica transmitted in the pathogenesis of amebiasis?What is the disease course of Entamoeba histolytica infection and amebiasis?How is amebiasis diagnosed?What are the treatment options for amebiasis?What is the role of Entamoeba histolytica in the pathogenesis of amebiasis?Following ingestion, what is the life cycle of Entamoeba histolytica?What is the immunopathology of Entamoeba histolytica in the pathogenesis of amebiasis?How is amebiasis spread to the liver?What is the immune response to Entamoeba histolytica in the pathogenesis of amebiasis?What causes amebiasis and how does it manifest?Which Entamoeba species are pathogenic?How is Entamoeba histolytica transmitted?What is the prevalence of amebiasis in the US?Who is at highest risk for developing amebiasis?What is the mortality rate for amebiasis in the US?What is the global prevalence of amebiasis?What is the association between amebiasis and HIV/AIDS?How does the prevalence of amebiasis vary by age?How does the prevalence of amebiasis vary by sex?How does the prevalence of amebiasis vary by race?In which groups is the severity of amebiasis increased?What is the prognosis of amebiasis?What actions can reduce the risk of amebiasis in travelers to endemic areas?What is the clinical spectrum of amebiasis?What are the signs and symptoms of amebic colitis?What are the signs and symptoms of liver abscess in amebiasis?What is ameboma?What is pleuropulmonary amebiasis?What is cerebral amebiasis?What is amebic peritonitis?What is amebic pericarditis?What are genitourinary symptoms of amebiasis?How common is appendicitis a symptom of amebiasis?What are the physical findings suggestive of amebiasis?What are possible complications of amebic colitis?What are possible complications of amebiasis-induced liver abscess?What are possible complications of amebiasis?What conditions should be included in the differential diagnoses of amebiasis?How is amebic liver abscess distinguished from other hepatic conditions?What are the differential diagnoses for Amebiasis?What is the role of lab tests in the diagnosis of amebiasis?What is the role of microscopy in the diagnosis of amebiasis?What is the role of cultures in the diagnosis of amebiasis?What is the role of ELISA in the diagnosis of amebiasis?What is the prevalence of serum antibodies in patients with amebiasis?How are serum antibodies detected in amebiasis?What is the role of IFA in the diagnosis of amebiasis?What is the role of IHA in the diagnosis of amebiasis?Which techniques are used to detect amebiasis antibodies?What is the role of PCR in the diagnosis of amebiasis?What is the role of loop-mediated isothermal amplification (LAMP) assay in the diagnosis of amebiasis?What is the role of radiography in the evaluation of amebiasis?What is the role of ultrasonography and CT scanning in the evaluation of amebiasis?What is the role of MRI in the evaluation of amebiasis?What is the role of liver aspiration in the diagnosis of amebiasis?How is liver abscess aspirate characterized in amebiasis?What is the role of colonoscopy in the diagnosis of amebiasis?When are intestinal biopsies indicated in the evaluation of amebiasis?Which histopathologic findings suggest amebiasis?What is the histopathological hallmark of amebic colitis?What chemical stains can be used in the histological detection of Entamoeba histolytica in amebiasis?What are the treatment options for amebiasis?When is hospitalization indicated for the treatment of amebiasis?How is intestinal amebiasis distinguished from inflammatory bowel disease (IBD)?When is treatment of asymptomatic amebiasis indicated?What medications are used in the treatment of amebiasis?What is the treatment for amebic colitis?What is the treatment for amebic liver abscess?What is the treatment for hepatic amebiasis?What is the role of broad-spectrum antibiotics in the treatment of amebiasis?When is surgical intervention indicated in the treatment of amebic colitis?When is surgical intervention indicated for amebiasis?When is drainage of amebic liver abscess necessary?How is amebiasis prevented?What is the role of vaccination in the prevention of amebiasis?How should asymptomatic amebiasis be treated?How should amebic be treated?How should amebic liver abscess be treated?Which medications in the drug class Antibiotics, Other are used in the treatment of Amebiasis?

Author

Vinod K Dhawan, MD, FACP, FRCPC, FIDSA, Professor, Department of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Infectious Diseases, Rancho Los Amigos National Rehabilitation Center

Disclosure: Nothing to disclose.

Coauthor(s)

J Robert Cantey, MD, Professor, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina

Disclosure: Nothing to disclose.

Kerry O Cleveland, MD, Professor of Medicine, University of Tennessee College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Acknowledgements

Michael Stuart Bronze, MD Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Vinod K Dhawan, MD, FACP, FRCP(C), FIDSA Professor, Department of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Infectious Diseases, Rancho Los Amigos National Rehabilitation Center

Vinod K Dhawan, MD, FACP, FRCP(C), FIDSA is a member of the following medical societies: American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Royal College of Physicians and Surgeons of Canada

Disclosure: Pfizer Inc Honoraria Speaking and teaching

Maria A Horga, MD Assistant Professor, Department of Pediatric Infectious Diseases, Bristol-Myers Squibb

Disclosure: Nothing to disclose.

Alexandre Lacasse, MD, MSc Internal Medicine Faculty, Assistant Director, Medicine Clinic, Infectious Disease Consultant, St Mary's Health Center

Alexandre Lacasse, MD, MSc is a member of the following medical societies: American College of Physicians, American Medical Association, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Klaus-Dieter Lessnau, MD, FCCP Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Thomas R Naparst, MD Clinical Instructor in Emergency Medicine, New York University School of Medicine; Consulting Staff, Department of Emergency Medicine, New York Downtown Hospital

Thomas R Naparst, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Michael D Nissen, MBBS, FRACP, FRCPA Associate Professor in Biomolecular, Biomedical Science & Health, Griffith University; Director of Infectious Diseases and Unit Head of Queensland Paediatric Infectious Laboratory, Sir Albert Sakzewski Viral Research Centre, Royal Children's Hospital

Michael D Nissen, MBBS, FRACP, FRCPA is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Pediatric Infectious Diseases Society, Royal Australasian College of Physicians, and Royal College of Pathologists of Australasia

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Robert Swords, MD Fellow, Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Martin Weisse, MD Program Director, Associate Professor, Department of Pediatrics, West Virginia University

Martin Weisse, MD is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References

  1. Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc. 2008 Oct. 83(10):1154-9; quiz 1159-60. [View Abstract]
  2. Grecu F, Bulgariu T, Blanaru O, Dragomir C, Lunca C, Stratan I, et al. Invasive amebiasis. Chirurgia (Bucur). 2006 Sep-Oct. 101(5):539-42. [View Abstract]
  3. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N Engl J Med. 2003 Apr 17. 348(16):1565-73. [View Abstract]
  4. Stanley SL Jr. Amoebiasis. Lancet. 2003 Mar 22. 361(9362):1025-34. [View Abstract]
  5. Shirley DT, Farr L, Watanabe K, Moonah S. A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis. Open Forum Infect Dis. 2018 Jul. 5 (7):ofy161. [View Abstract]
  6. Ravdin JI, Stanley P, Murphy CF, Petri WA Jr. Characterization of cell surface carbohydrate receptors for Entamoeba histolytica adherence lectin. Infect Immun. 1989 Jul. 57(7):2179-86. [View Abstract]
  7. Ximénez C, Cerritos R, Rojas L, Dolabella S, Morán P, Shibayama M, et al. Human amebiasis: breaking the paradigm?. Int J Environ Res Public Health. 2010 Mar. 7(3):1105-20. [View Abstract]
  8. Haque R, Mondal D, Duggal P, Kabir M, Roy S, Farr BM, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun. 2006 Feb. 74(2):904-9. [View Abstract]
  9. Seydel KB, Stanley SL Jr. Entamoeba histolytica induces host cell death in amebic liver abscess by a non-Fas-dependent, non-tumor necrosis factor alpha-dependent pathway of apoptosis. Infect Immun. 1998 Jun. 66(6):2980-3. [View Abstract]
  10. Que X, Reed SL. Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev. 2000 Apr. 13(2):196-206. [View Abstract]
  11. Kelsall BL, Ravdin JI. Degradation of human IgA by Entamoeba histolytica. J Infect Dis. 1993 Nov. 168(5):1319-22. [View Abstract]
  12. Reed SL, Keene WE, McKerrow JH, Gigli I. Cleavage of C3 by a neutral cysteine proteinase of Entamoeba histolytica. J Immunol. 1989 Jul 1. 143(1):189-95. [View Abstract]
  13. Abhyankar MM, Shrimal S, Gilchrist CA, Bhattacharya A, Petri WA Jr. The Entamoeba histolytica serum-inducible transmembrane kinase EhTMKB1-9 is involved in intestinal amebiasis. Int J Parasitol Drugs Drug Resist. 2012 Dec. 2:243-248. [View Abstract]
  14. Seydel KB, Li E, Swanson PE, Stanley SL Jr. Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun. 1997 May. 65(5):1631-9. [View Abstract]
  15. Stenson WF, Zhang Z, Riehl T, Stanley SL Jr. Amebic infection in the human colon induces cyclooxygenase-2. Infect Immun. 2001 May. 69(5):3382-8. [View Abstract]
  16. Braga LL, Ninomiya H, McCoy JJ, Eacker S, Wiedmer T, Pham C, et al. Inhibition of the complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica. J Clin Invest. 1992 Sep. 90(3):1131-7. [View Abstract]
  17. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev. 2007 Jul. 20(3):511-32, table of contents. [View Abstract]
  18. Shimokawa C, Kabir M, Taniuchi M, Mondal D, Kobayashi S, Ali IK, et al. Entamoeba moshkovskii is associated with diarrhea in infants and causes diarrhea and colitis in mice. J Infect Dis. 2012 Sep 1. 206 (5):744-51. [View Abstract]
  19. Verkerke HP, Petri WA Jr, Marie CS. The dynamic interdependence of amebiasis, innate immunity, and undernutrition. Semin Immunopathol. 2012 Nov. 34(6):771-85. [View Abstract]
  20. Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA, et al. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect. 2009 Jul. 59 (1):19-27. [View Abstract]
  21. Gunther J, Shafir S, Bristow B, Sorvillo F. Short report: Amebiasis-related mortality among United States residents, 1990-2007. Am J Trop Med Hyg. 2011 Dec. 85 (6):1038-40. [View Abstract]
  22. Gunther J, Shafir S, Bristow B, Sorvillo F. Short report: Amebiasis-related mortality among United States residents, 1990-2007. Am J Trop Med Hyg. 2011 Dec. 85(6):1038-40. [View Abstract]
  23. Valenzuela O, Morán P, Gómez A, Cordova K, Corrales N, Cardoza J, et al. Epidemiology of amoebic liver abscess in Mexico: the case of Sonora. Ann Trop Med Parasitol. 2007 Sep. 101(6):533-8. [View Abstract]
  24. van Hal SJ, Stark DJ, Fotedar R, Marriott D, Ellis JT, Harkness JL. Amoebiasis: current status in Australia. Med J Aust. 2007 Apr 16. 186(8):412-6. [View Abstract]
  25. Ximénez C, Morán P, Rojas L, Valadez A, Gómez A. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol. 2009 Dec. 9(6):1023-32. [View Abstract]
  26. Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res. 2006 Feb. 37(2):266-9. [View Abstract]
  27. Stanley SL Jr. Amoebiasis. Lancet. 2003 Mar 22. 361 (9362):1025-34. [View Abstract]
  28. Tengku SA, Norhayati M. Public health and clinical importance of amoebiasis in Malaysia: a review. Trop Biomed. 2011 Aug. 28(2):194-222. [View Abstract]
  29. Caballero-Salcedo A, Viveros-Rogel M, Salvatierra B, Tapia-Conyer R, Sepulveda-Amor J, Gutierrez G, et al. Seroepidemiology of amebiasis in Mexico. Am J Trop Med Hyg. 1994 Apr. 50(4):412-9. [View Abstract]
  30. Blessmann J, Van Linh P, Nu PA, Thi HD, Muller-Myhsok B, Buss H, et al. Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in central Vietnam. Am J Trop Med Hyg. 2002 May. 66(5):578-83. [View Abstract]
  31. Bowley DM, Loveland J, Omar T, Pitcher GJ. Human immunodeficiency virus infection and amebiasis. Pediatr Infect Dis J. 2006 Dec. 25(12):1192-3. [View Abstract]
  32. Brindicci G, Picciarelli C, Fumarola L, Carbonara S, Stano F, Ciracì E, et al. Amoebic hepatic abscesses in an HIV-positive patient. AIDS Patient Care STDS. 2006 Sep. 20(9):606-11. [View Abstract]
  33. Chen Y, Zhang Y, Yang B, Qi T, Lu H, Cheng X, et al. Seroprevalence of Entamoeba histolytica infection in HIV-infected patients in China. Am J Trop Med Hyg. 2007 Nov. 77(5):825-8. [View Abstract]
  34. Hsu MS, Hsieh SM, Chen MY, Hung CC, Chang SC. Association between amebic liver abscess and human immunodeficiency virus infection in Taiwanese subjects. BMC Infect Dis. 2008 Apr 16. 8:48. [View Abstract]
  35. Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis. 2007 Nov 1. 45(9):1208-13. [View Abstract]
  36. Park WB, Choe PG, Jo JH, Kim SH, Bang JH, Kim HB, et al. Amebic liver abscess in HIV-infected patients, Republic of Korea. Emerg Infect Dis. 2007 Mar. 13(3):516-7. [View Abstract]
  37. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am J Trop Med Hyg. 2006 Nov. 75(5):1023. [View Abstract]
  38. Hung CC, Ji DD, Sun HY, Lee YT, Hsu SY, Chang SY, et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl Trop Dis. 2008 Feb 27. 2(2):e175. [View Abstract]
  39. Muzaffar J, Madan K, Sharma MP, Kar P. Randomized, single-blind, placebo-controlled multicenter trial to compare the efficacy and safety of metronidazole and satranidazole in patients with amebic liver abscess. Dig Dis Sci. 2006 Dec. 51(12):2270-3. [View Abstract]
  40. Hung CC, Wu PY, Chang SY, Ji DD, Sun HY, Liu WC, et al. Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case-control study. Am J Trop Med Hyg. 2011 Jan. 84(1):65-9. [View Abstract]
  41. Acuna-Soto R, Maguire JH, Wirth DF. Gender distribution in asymptomatic and invasive amebiasis. Am J Gastroenterol. 2000 May. 95(5):1277-83. [View Abstract]
  42. Nagata N, Shimbo T, Akiyama J, Nakashima R, Nishimura S, Yada T. Risk factors for intestinal invasive amebiasis in Japan, 2003-2009. Emerg Infect Dis. 2012 May. 18(5):717-24. [View Abstract]
  43. Aristizábal H, Acevedo J, Botero M. Fulminant amebic colitis. World J Surg. 1991 Mar-Apr. 15(2):216-21. [View Abstract]
  44. Andrade JE, Mederos R, Rivero H, Sendzischew MA, Soaita M, Robinson MJ, et al. Amebiasis presenting as acute appendicitis. South Med J. 2007 Nov. 100(11):1140-2. [View Abstract]
  45. Rao S, Solaymani-Mohammadi S, Petri WA Jr, Parker SK. Hepatic amebiasis: a reminder of the complications. Curr Opin Pediatr. 2009 Feb. 21(1):145-9. [View Abstract]
  46. Goswami A, Dadhich S, Bhargava N. Colonic involvement in amebic liver abscess: does site matter?. Ann Gastroenterol. 2014. 27(2):156-161. [View Abstract]
  47. Hardin RE, Ferzli GS, Zenilman ME, Gadangi PK, Bowne WB. Invasive amebiasis and ameboma formation presenting as a rectal mass: An uncommon case of malignant masquerade at a western medical center. World J Gastroenterol. 2007 Nov 14. 13(42):5659-61. [View Abstract]
  48. Loulergue P, Mir O. Pleural empyema secondary to amebic liver abscess. Int J Infect Dis. 2009 May. 13(3):e135-6. [View Abstract]
  49. Dhawan VK, Malik SK. Acute pneumonia in the right lower lobe. Chest. 1975 Mar. 67(3):346-7. [View Abstract]
  50. Otan E, Akbulut S, Kayaalp C. Amebic acute appendicitis: systematic review of 174 cases. World J Surg. 2013 Sep. 37(9):2061-73. [View Abstract]
  51. Sodhi KS, Ojili V, Sakhuja V, Khandelwal N. Hepatic and inferior vena caval thrombosis: vascular complication of amebic liver abscess. J Emerg Med. 2008 Feb. 34(2):155-7. [View Abstract]
  52. Abd-Alla MD, Jackson TF, Gathiram V, el-Hawey AM, Ravdin JI. Differentiation of pathogenic Entamoeba histolytica infections from nonpathogenic infections by detection of galactose-inhibitable adherence protein antigen in sera and feces. J Clin Microbiol. 1993 Nov. 31(11):2845-50. [View Abstract]
  53. Haque R, Mollah NU, Ali IK, Alam K, Eubanks A, Lyerly D, et al. Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests. J Clin Microbiol. 2000 Sep. 38(9):3235-9. [View Abstract]
  54. Helmy MM, Rashed LA, Abdel-Fattah HS. Detection and differentiation of Entamoeba histolytica and Entamoeba dispar isolates in clinical samples by PCR. J Egypt Soc Parasitol. 2007 Apr. 37(1):257-74. [View Abstract]
  55. Singh A, Houpt E, Petri WA. Rapid Diagnosis of Intestinal Parasitic Protozoa, with a Focus on Entamoeba histolytica. Interdiscip Perspect Infect Dis. 2009. 2009:547090. [View Abstract]
  56. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev. 2003 Oct. 16(4):713-29. [View Abstract]
  57. Saidin S, Othman N, Noordin R. Update on laboratory diagnosis of amoebiasis. Eur J Clin Microbiol Infect Dis. 2019 Jan. 38 (1):15-38. [View Abstract]
  58. Shamsuzzaman SM, Haque R, Hasin SK, Hashiguchi Y. Evaluation of indirect fluorescent antibody test and enzyme-linked immunosorbent assay for diagnosis of hepatic amebiasis in Bangladesh. J Parasitol. 2000 Jun. 86(3):611-5. [View Abstract]
  59. Ahmad N, Khan M, Hoque MI, Haque R, Mondol D. Detection of Entamoeba histolytica DNA from liver abscess aspirate using polymerase chain reaction (PCR): a diagnostic tool for amoebic liver abscess. Bangladesh Med Res Counc Bull. 2007 Apr. 33(1):13-20. [View Abstract]
  60. Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. PCR detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in stool samples from Sydney, Australia. J Clin Microbiol. 2007 Mar. 45(3):1035-7. [View Abstract]
  61. Khairnar K, Parija SC. A novel nested multiplex polymerase chain reaction (PCR) assay for differential detection of Entamoeba histolytica, E. moshkovskii and E. dispar DNA in stool samples. BMC Microbiol. 2007 May 24. 7:47. [View Abstract]
  62. Stark D, van Hal S, Fotedar R, Butcher A, Marriott D, Ellis J, et al. Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis. J Clin Microbiol. 2008 May. 46(5):1678-81. [View Abstract]
  63. Singh P, Mirdha BR, Ahuja V, Singh S. Loop-mediated isothermal amplification (LAMP) assay for rapid detection of Entamoeba histolytica in amoebic liver abscess. World J Microbiol Biotechnol. 2013 Jan. 29(1):27-32. [View Abstract]
  64. Misra SP, Misra V, Dwivedi M. Ileocecal masses in patients with amebic liver abscess: etiology and management. World J Gastroenterol. 2006 Mar 28. 12(12):1933-6. [View Abstract]
  65. Nagata N, Shimbo T, Akiyama J, Nakashima R, Niikura R, Nishimura S, et al. Predictive value of endoscopic findings in the diagnosis of active intestinal amebiasis. Endoscopy. 2012 Apr. 44(4):425-8. [View Abstract]
  66. Gonzales ML, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2009 Apr 15. CD006085. [View Abstract]
  67. Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis. 1999 Nov. 29(5):1117-25. [View Abstract]
  68. Salles JM, Salles MJ, Moraes LA, Silva MC. Invasive amebiasis: an update on diagnosis and management. Expert Rev Anti Infect Ther. 2007 Oct. 5(5):893-901. [View Abstract]
  69. Kimura M, Nakamura T, Nawa Y. Experience with intravenous metronidazole to treat moderate-to-severe amebiasis in Japan. Am J Trop Med Hyg. 2007 Aug. 77(2):381-5. [View Abstract]
  70. Moon TD, Oberhelman RA. Antiparasitic therapy in children. Pediatr Clin North Am. 2005 Jun. 52(3):917-48, viii. [View Abstract]
  71. Gonzales MLM, Dans LF, Sio-Aguilar J. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2019 Jan 9. 1:CD006085. [View Abstract]
  72. Bammigatti C, Ramasubramanian NS, Kadhiravan T, Das AK. Percutaneous needle aspiration in uncomplicated amebic liver abscess: a randomized trial. Trop Doct. 2013 Jan. 43(1):19-22. [View Abstract]
  73. Cordel H, Prendki V, Madec Y, Houze S, Paris L, Bourée P, et al. Imported amoebic liver abscess in France. PLoS Negl Trop Dis. 2013. 7 (8):e2333. [View Abstract]
  74. McGregor A, Brown M, Thway K, Wright SG. Fulminant amoebic colitis following loperamide use. J Travel Med. 2007 Jan-Feb. 14 (1):61-2. [View Abstract]
  75. Athié-Gutiérrez C, Rodea-Rosas H, Guízar-Bermúdez C, Alcántara A, Montalvo-Javé EE. Evolution of surgical treatment of amebiasis-associated colon perforation. J Gastrointest Surg. 2010 Jan. 14(1):82-7. [View Abstract]
  76. Jha AK, Das G, Maitra S, Sengupta TK, Sen S. Management of large amoebic liver abscess--a comparative study of needle aspiration and catheter drainage. J Indian Med Assoc. 2012 Jan. 110(1):13-5. [View Abstract]
  77. Shirley DA, Moonah S. Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review. PLoS Negl Trop Dis. 2016 Jul. 10 (7):e0004879. [View Abstract]
  78. Chaudhry OA, Petri WA Jr. Vaccine prospects for amebiasis. Expert Rev Vaccines. 2005 Oct. 4(5):657-68. [View Abstract]
  79. Snow MJ, Stanley SL Jr. Recent progress in vaccines for amebiasis. Arch Med Res. 2006 Feb. 37(2):280-7. [View Abstract]
  80. Stanley SL Jr. Vaccines for amoebiasis: barriers and opportunities. Parasitology. 2006. 133 Suppl:S81-6. [View Abstract]
  81. Quach J, St-Pierre J, Chadee K. The future for vaccine development against Entamoeba histolytica. Hum Vaccin Immunother. 2014 Feb 6. 10(6):[View Abstract]
  82. Kikuchi T, Koga M, Shimizu S, Miura T, Maruyama H, Kimura M. Efficacy and safety of paromomycin for treating amebiasis in Japan. Parasitol Int. 2013 Dec. 62(6):497-501. [View Abstract]

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythrocytes, and all 3 have nuclei with small, centrally located karyosomes.

Life cycle of Entamoeba histolytica.

Entamoeba histolytica cyst. Image courtesy of Centers for Disease Control and Prevention.

Entamoeba histolytica trophozoite. Image courtesy of Centers for Disease Control and Prevention.

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythrocytes, and all 3 have nuclei with small, centrally located karyosomes.

Entamoeba histolytica in liver aspirate, trichrome stain. Image courtesy of Centers for Disease Control and Prevention.

Gross pathology of intestinal ulcers due to amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Histopathology of amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Histopathology of typical flask-shaped ulcer of intestinal amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Trichrome stain of Entamoeba histolytica cyst in amebiasis. Each cyst has 4 nuclei with characteristically centrally located karyosomes. Cysts measure 12-15 mm.

Trichrome stain of Entamoeba histolytica trophozoites in amebiasis. Two diagnostic characteristics are observed. Two trophozoites have ingested erythrocytes, and all 3 have nuclei with small, centrally located karyosomes.

Trichrome stain of Entamoeba histolytica cyst in amebiasis. Each cyst has 4 nuclei with characteristically centrally located karyosomes. Cysts measure 12-15 mm.

Entamoeba histolytica trophozoite. Image courtesy of Centers for Disease Control and Prevention.

Entamoeba histolytica cyst. Image courtesy of Centers for Disease Control and Prevention.

Life cycle of Entamoeba histolytica.

Gross pathology of intestinal ulcers due to amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Histopathology of typical flask-shaped ulcer of intestinal amebiasis. Image courtesy of Centers for Disease Control and Prevention.

Entamoeba histolytica in liver aspirate, trichrome stain. Image courtesy of Centers for Disease Control and Prevention.

Histopathology of amebiasis. Image courtesy of Centers for Disease Control and Prevention.